baber/WOPTO huggingface dataset:
Patent NZ-326452-A (NZ)
Title: Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
Inventor: KOCHANNY MONICA
IPC: C07D401/12
Filed: 1997-02-07
Abstract: The application is directed to benzamidine derivatives substituted by amino acid and hydroxy acid derivatives, which are useful as anti-coagulants, where:  A is C(R8) or N; Z1 and Z2 each are O, N(R13), S or OCH2 ; and the other moieties are as defined in the specification. Also included are pharmaceutical compositions containing these compounds, and methods of using the compounds to treat disease-states characterized by thrombotic activity.
Patent NZ-334762-A (NZ)
Title: Human DNase I variants having binding affinity to actin
Inventor: ROBERT A LAZARUS
IPC: C12N15/55
Filed: 1999-03-22
Abstract: These actin-resistant variants of human DNase 1, which are useful in treating pulmonary disorders, have 90% identity with the amino acid shown and have at least one amino acid substitution for another at the positions:  His44, Leu45, Val48, Gly49, Leu52, Asp53, Asn56, His64, Tyr65, Val66, Val67, Ser68, Glu69 or Ala114.
Patent NZ-335316-A (NZ)
Title: Tablets containing a sweetening mixture containing 1,1-gps (1-o-<alpha>-d glucopyranosyl-d-sorbitol)
Inventor: RAPP KNUT M
IPC: A23L27/30
Filed: 1997-08-09
Abstract: The present invention relates to a compressed formulation containing 1,1-GPS (1-O-alpha-D-glucopyranosyl-D-sorbitol) or a mixture of sweetening agents composed of 1,1-GPS, 6-0-alpha-D-glucopyranosyl-D-sorbitol (1,6-GPS) and 1-0-alpha-D-glucopyranosyl-D-mannitol (1,1 GPM).
Patent NZ-337153-A (NZ)
Title: Harvester with rear bin tipper depositing bin onto ground as harvester moves
Inventor: SLACK MARK
IPC: A01D33/14
Filed: 1999-05-12
Abstract: in tipper 39 is able to deposit the rearmost edge of  a bin so that it is dragged of and onto the ground.
Patent NZ-503001-A (NZ)
Title: Use of an androgen antagonist in therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
Inventor: LEDERMAN SETH
IPC: A61K48/00
Filed: 1998-08-27
Abstract: An inhibitor of androgen/androgen receptor binding or signaling is used for treating anorexia, anorexia nervosa or pathologically under weight condition.  The inhibitor can be flutamide, nilutamide, zanoterone, casdex or  cimetidine.
Patent NZ-504222-A (NZ)
Title: Non RCR Leuconostoc plasmid capable of being transferred into lactic acid bacteria and its use as cloning and expressing tool
Inventor: BIET FRANCK
IPC: C12N1/21
Filed: 1998-11-02
Abstract: A plasmid which has a mode of replication which is  not of  the  RCR  type and which is capable of being transferred stably  in  host  lactic acid bacteria which  belong  to  at least  three different genera, wherein the plasmid comprises the nucleotide sequence SEQ ID NO: 1.
Patent NZ-504349-A (NZ)
Title: Solvent based compositions containing a non-gelled polymeric composition
Inventor: ANDERSON JEFFREY L
IPC: C08G81/02
Filed: 1998-11-12
Abstract: A solvent based composition comprising: i) A non aqueous solvent, and ii) A non-gelled polymeric composition comprising the reaction product of an A polymer which is an addition polymer having 3.5 or more reactive functional groups per polymer chain and a B polymer having 2 to 3 functional groups per polymer chain that are co-reactive with the reactive functional groups of the A polymer, where substantially all of the co-reactive functional groups of the B polymer have been co-reacted and the molar ratio of A polymer to B polymer is 3:1 to 2:1.7.
Patent NZ-505066-A (NZ)
Title: Polypeptides having aminopeptidase activity and nucleic acids encoding same
Inventor: BROWN KIMBERLEY
IPC: A23J3/34
Filed: 1998-11-13
Abstract: An isolated polypeptide having aminopeptidase activity, selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has at least 50% identity with amino acids 33 to 674 of SEQ ID NO: 2; (b) a polypeptide which is encoded by a nucleic acid sequence which hybridizes under medium stringency conditions with (i) the nucleic acid sequence of SEQ ID NO: 1 or (ii) its complementary strand; or a subsequence thereof of at least 100 nucleotides; (c) an allelic variant of (a) or (b); (d) a fragment of (a), (b), or (c), wherein the fragment has aminopeptidase activity; and (e) a polypeptide which (i) has aminopeptidase activity in the pH range between pH 5.0-8.5 measured at 37 C, (i) has an isoelectric point in the range of 7.4-8.5; (iii) has aminopeptidase activity in the temperature range of 20-55 C, measured at pH 7.5 using Gly pNA in Tris-cl buffer; (iv) hydrolyzes Ala-pNA, Gly-pNA, Leu-pNA, Glu-pNA, Asp-pNA, Lys-pNA, Ile-pNA and Val-pNA; (v) does not hydrolyze Phe-pNA nor Pro-pNA; (vi) is not inhibited by phenylmethanesulfonyl fluoride, slightly inhibited by EDTA, di-isopropyl fluoro phosphate, p-chloromercuribenzoic acid and iodoacetic acid, completely inhibited by o phenanthroline, and/or (vii) is obtained from a strain belonging to Sphingomonas and has a molecular mass of 67 5 kDa.
Patent NZ-505756-A (NZ)
Title: Process for preparing rigid polyurethane or urethane-modified polyisocyanurate foams
Inventor: DE VOS RIK
IPC: C08G18/76
Filed: 1999-01-21
Abstract: A process for preparing rigid polyurethane or urethane modified polyisocyanurate foams comprises reacting an organic polyisocyanate with a polyfunctional isocyanate reactive component in the presence of a blowing agent mixture containing 50-90% by weight of cyclopentane and from 10-50% by weight of a mixture of isopentane and/or n-pentane and isobutane and/or n-butane wherein the weight ratio of isopentane and/or n-pentane over isobutene and/or n-butane is between 5/95 and 95/5.
Patent NZ-506575-A (NZ)
Title: Electroluminescent display with areas having congruent phosphor and conductive materials and with a dielectric layer covering all of the display
Inventor: TUCKER JOHN KENNETH
IPC: H05B33/12
Filed: 1999-01-28
Abstract: The electroluminescent display includes a first substantially transparent or translucent conductive layer (11) with a phosphor or the like layer (12a, 12b) deposited thereon. A layer of dielectric (13) is deposited upon the phosphor or the like layer and a second conductive layer (14a, 14b) is deposited upon the dielectric layer. The second conductive layer is comprised of a number of areas (14a, 14b) shaped to be substantially congruent with the shaped areas (12a, 12b) of the phosphor layer. The layer of dielectric material (13) interposed between the phosphor layer and the second conductive layer covers substantially all of the display. The unitary dielectric layer (13) flattens the print profile so that conductive traces (17) undergo a smooth transition between the shaped areas (14a, 14b), thus reducing burnouts at transition boundaries. The dielectric layer (13) is preferably opaque, to preventive conductive traces (17) showing through the light emitting side (50) of the display.
Patent NZ-507971-A (NZ)
Title: Carbon based electrodes
Inventor: CALVER TIMOTHY JAMES
IPC: H01M12/08
Filed: 1999-05-05
Abstract: A carbon based electrode for the electrochemical reduction of sulfur or oxygen comprising a porous particulate activated carbon bonded with a polymeric binder material, a method for making the electrode, and an energy storage cell comprising the electrode.  The activated carbon is prepared from a lignocellulosic material that has a particle size from 200-850 mm, a pore volume of 0.45-1.0cm3 per gram and a surface area from 800-1500 m2/g.  The binder is used in an amount less than 25% by weight based on the mixture of activated carbon and binder.
Patent NZ-515080-A (NZ)
Title: Battery pack latching assembly with dual detent locking for fastener driving tool
Inventor: BEUTOW ROBERT SCOTT
IPC: B25C1/00
Filed: 2001-10-29
Abstract: A battery pack latching assembly (210) for use within a portable fastener driving tool.  The battery pack assembly comprises a battery case (212), at least one battery power cell (216) disposed internally within the battery case, electrical contacts (218) disposed upon the battery pack assembly for electrical connection to electrical power contacts mounted upon the portable tool, and a dual latching detent system.  The dual latching detent system comprises first and second latching detents (230, 236) for operative cooperation with a single window aperture (220) of the tool, mounted upon the battery case for respectively lockingly latching the battery pack assembly at first and second positions upon the portable tool.  When the first latching detent is engaged with the single window aperture of the tool so as to lockingly engage the battery pack assembly at the first position, the electrical contacts of the battery pack assembly will be electrically disengaged from the power contacts of the portable tool whereby the portable tool will be disposed in an OFF state.  When the second latching detent is engaged with the single window aperture of the tool so as to lockingly engage the battery pack assembly at the second position, the electrical contacts of the battery pack assembly will be electrically engaged with the power contacts of the portable tool whereby the portable tool will be disposed in an ON state.
Patent NZ-524740-A (NZ)
Title: Pyrazole derivatives for the treatment of viral diseases mediated by the human immunodeficiency virus (HIV)
Inventor: DYMOCK BRIAN WILLIAM
IPC: A61P31/18
Filed: 2001-10-04
Abstract: Pyrazole derivatives of formula (I) that are inhibitors of the human immunodeficiency virus, a process for their manufacture, pharmaceutical compositions and the use of such compounds in medicine are disclosed, wherein R1, R2, R3, A & X are as defined in the specification. In particular, the compounds of formula (I) are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication, and are useful for the treatment of diseases mediated by the human immunodeficiency virus (HIV). Consequently these compounds may be advantageously used as therapeutic agents for HIV mediated process.
Patent NZ-535043-A (NZ)
Title: Human fetal bladder-derived epithelial cells
Inventor: LI RONG-HAO
IPC: C12Q1/68
Filed: 2003-02-12
Abstract: Disclosed is a substantially pure population of human foetal urinary bladder-derived epithelial cells wherein said cells have a capacity to differentiate into bladder or prostate epithelium and wherein said cells are positive for molecular marker H19 imprinted gene mRNA and lacking alpha-actin expression.
Patent NZ-538630-A (NZ)
Title: Propulsion device for a personal flight device with fans rotating in the same direction
Inventor: MARTIN GLENN NEIL
Filed: 2005-03-04
Abstract: A personal flight device has a housing securable to a pilot. The device also includes at least one pair of fans with one fan mounted to one side of the housing and the other fan mounted to the other side of the housing. Each fan rotates about an axis of rotation which is fixed relative to the housing. At least one engine is mounted on the housing for driving the fans wherein both fans rotate in the same direction for producing thrust.
Patent NZ-544954-A (NZ)
Title: Otoscope
Inventor: GOLDFAIN ERVIN
IPC: A61B1/227
Filed: 2004-07-26
Abstract: An otoscope permitting examination of a patient's ear is defined by an instrument head including a proximal end and a distal insertion portion that is insertable into the ear. The otoscope includes an imaging lens train disposed within the instrument head, wherein each of the imaging lens train, an eyepiece and a distal opening of said insertion portion are aligned along an optical axis. The otoscope further includes a focusing mechanism for selectively moving at least one of the imaging lens train and the optics contained within the eyepiece relative to one another along the optical axis. The imaging lens train and the optics in the eyepiece define an optical system such that an entrance pupil is substantially located in the distal insertion portion of the instrument head, thereby enabling the entire tympanic membrane to be viewed at once by the user.
Patent NZ-549867-A (NZ)
Title: Prodrugs of piperazine and substituted piperidine antiviral agents
Inventor: ZHANG ZHONGXING
IPC: A61K31/496
Filed: 2005-03-03
Abstract: Disclosed is a (phosphonooxy)methyl]pyrrolo[2,3-c]pryidin-3-yl] compound of Formula (I), Wherein W is N, V is carbon, R1 is halogen, R3 is 1,2,3-triazolyl attached at position N-1, E is hydrogen or a pharmaceutically acceptable mono or bis salt thereof and Y is defined as in the specification. Also disclosed is process to prepare said compounds.
Patent NZ-552640-A (NZ)
Title: Barbed sutures
Inventor: LEUNG JEFFERY C
IPC: A61B17/04
Filed: 2003-09-29
Abstract: A barbed suture for connecting tissue. The suture includes an elongated body and a plurality of barbs projecting from the body. Each barb causes the suture to resist movement in an opposite direction from which the barb faces. The disposition of the barbs on the body is a random disposition such that the relative radial and longitudinal spacing of the barbs along the body of the barbed suture is random, and the barbs face in random directions including at least one barb wherein the longitudinal axis of the at least one barb is not parallel to the longitudinal axis of the body of the barbed suture.
Patent NZ-554248-A (NZ)
Title: Inflatable nuclear prosthesis
Inventor: SUDDABY LOUBERT
IPC: A61F2/30
Filed: 2004-08-30
Abstract: A method and system for replacing a natural vertebral disc in a non-human animal is disclosed. A vertebral disc is removed defining an intervertebral space. A construct including an outer balloon (20) and an inner balloon (10) inside the outer balloon is inserted into the intervertebral space. A first liquid material (12) and a second liquid material (22) are injected to inflate the inner and the outer balloons respectively. The second liquid material is hardenable so as to form a stable mass (18) which conforms to the shape of the intervertebral space.
Patent NZ-556740-A (NZ)
Title: Gastroresistant pharmaceutical formulations containing rifaximin
Inventor: VISCOMI GIUSEPPE C
IPC: A61K31/395
Filed: 2006-03-06
Abstract: Disclosed is a pharmaceutical formulation comprising gastroresistant rifaximin microgranules, wherein the microgranule dimension is from between about 1 micron to about 900 microns in diameter; and the microgranules comprise polymers insoluble at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.7. Also disclosed is the use of the above formulation in the manufacture of a medicament for treating or preventing a condition selected from colitis, Crohn's disease and irritable bowel syndrome. Also disclosed is a method for making the above formulation comprising gastroresistant rifaximin microgranules.
Patent NZ-561317-A (NZ)
Title: Method and apparatus for managing uplink resource allocation in a communication system
Inventor: CASACCIA LORENZO
IPC: H04W74/06
Filed: 2006-03-10
Abstract: A method and apparatus for managing uplink: status flags (USFs) in a communication system are disclosed. The method comprises monitoring downlink timeslots with packet data channels (PDCHs) for USFs from a first downlink timeslot to a maximum numbered downlink timeslot numbered within a downlink time division multiple access (TDMA) frame. The maximum numbered downlink timeslot is the timeslot having the same number as the lowest numbered allocated transmission uplink timeslot in a corresponding uplink TDMA frame if a second lowest numbered allocated uplink timeslot is a circuit switched timeslot otherwise the maximum numbered downlink: timeslot is the timeslot having a number which is one higher than the number of the lowest numbered allocated transmission uplink timeslot. The method further comprises determining the lowest numbered allocated transmission uplink timeslot as a lowest numbered time slot over which an access terminal will transmit in the corresponding uplink TDMA frame. The method further comprises determining whether the timeslot which has a number which is one higher than the number of the lowest numbered allocated transmission timeslot is a circuit switched timeslot; setting the number of the maximum numbered downlink timeslot to a one higher number than a timeslot number corresponding to the lowest numbered allocated transmission uplink timeslot if the timeslot which has a one higher number than the lowest numbered allocated transmission timeslot is a circuit switched timeslot; and setting the number of the maximum numbered downlink timeslot to another timeslot number corresponding to the lowest numbered allocated transmission uplink timeslot if the timeslot which has a one higher number than the lowest numbered allocated transmission timeslot is not a circuit switched timeslot.
Patent NZ-563131-A (NZ)
Title: Tricyclic lactam compound as a hypoglycemic agent
Inventor: TANAKA HIDEYUKI
IPC: A61K31/551
Filed: 2006-04-28
Abstract: Disclosed is a lactam compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein U is C or N, Y is N, NH, CR', or CHR', the dashed lines are each single or double bonds as defined in the specification, and wherein the other substituents are as defined in the specification. Also disclosed is the use of the compound as a hypoglycemic agent, and for treating diabetes and related conditions.
Patent NZ-573689-A (NZ)
Title: C-glycolipids with enhanced TH-1 profile
Inventor: TSUJI MORIYA
IPC: A61K31/70
Filed: 2007-05-22
Abstract: Disclosed is a compound of formula (I), or a salt or ester thereof, wherein X is O or NH, Y is -CH=CH-, and the other substituents are as defined in the specification. Also disclosed is the use of the compound to selectively induce a Th1-type immune response, and to treat infection such as by HIV, HBV, or malaria, cancer, cell proliferative disorder, and autoimmune disease. Also disclosed is a method for preparing the compound.
Patent NZ-580312-A (NZ)
Title: Compositions and methods for controlling infestation
Inventor: BOWLES VERNON MORRISON
IPC: A01N35/04
Filed: 2007-04-05
Abstract: Disclosed is a method of treating pest infestations on or in a plant, domesticated or farming animal or environment comprising decreasing exsheathment of an invertebrate, decreasing excystment of an invertebrate, decreasing apolysis of an invertebrate, inhibiting metamorphosis of an invertebrate or killing an invertebrate with a bipyridine compound of formula (I). Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for treatment of an invertebrate pest infestation in a human resulting from decreasing exsheathment of an invertebrate, decreasing excystment of an invertebrate, decreasing apolysis of an invertebrate, inhibiting metamorphosis of an invertebrate or killing an invertebrate. Example of dipyridine compounds of formula (I) is 5,5'-dimenthyl-2,2'-dipyridyl.
Patent NZ-581109-A (NZ)
Title: New deer stem cell lines, their application and culture methods
Inventor: CEGIELSKI MAREK
IPC: C12N5/077
Filed: 2007-12-10
Abstract: A stable, immortal stem cell line derived from the tip lateral fragments of growing deer antlers and deposited under the DSMZ accession DSM ACC2854. The cell line can be used for xenogenic implantation for reconstruction of a connective tissue lesion in cartilage, bone or adipose tissue.
Patent NZ-585995-A (NZ)
Title: 1,2,4-oxadiazole compounds for the treatment of autoimmune diseases
Inventor: HEER JAG PAUL
IPC: A61K31/55
Filed: 2008-12-19
Abstract: Disclosed is a compound of formula (I) e.g. 3-[7-(5-{ 3-chloro-4-[(1-methylethyl)oxy]phenyl} -1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydro-1H-2-benzazepin-1-yl]propanamide or a pharmaceutically acceptable salt thereof wherein for use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and noninsulin dependant diabetes.
Patent NZ-587380-A (NZ)
Title: Inhibitors of the chemokine receptor CxCR3
Inventor: THORPE DAVID S
IPC: C07D295/033
Filed: 2009-02-18
Abstract: Disclosed is a 3-(amido or sulfamido)-4-(4-substituted-azinyl)benzamide or benzsulfonamide compound of formula (I) where Q and Y are CO or SO2, X is halo, m is 1-3, R5 is a monovalent group as described or is a spiro ring as described, and wherein the other substituents are as described in the specification. Also disclosed is the use of the compound to treat CxCR3 chemokine receptor mediated diseases or conditions.
Patent NZ-589743-A (NZ)
Title: Anxiolytic composition containing alphas1-casein-derived peptides
Inventor: BALANDRAS FREDERIQUE
IPC: A61K38/17
Filed: 2009-06-05
Abstract: Disclosed is the use of a peptide according to SEQ ID No. 1 (YLGYL) and/or a peptide according to SEQ ID No. 2 (YLGYLE) for the production of a drug for treating anxiety, sleep disorders and epilepsy. Further disclosed is a composition comprising a hydrolysate or a fraction of a hydrolysate of ?s1-casein containing an effective amount of a peptide according to SEQ ID No.1.
Patent NZ-590987-A (NZ)
Title: Quinuclidine carbonate derivatives and medicinal composition thereof
Inventor: AMARI GABRIELE
IPC: A61K31/439
Filed: 2009-07-21
Abstract: Disclosed are 3-(alkoxycarbonyloxy)-1-(alkyl)-1-azonia-bicyclo[2.2.2]octane derivatives as represented by the general formula (I), wherein A is (a) optionally substituted aryl, (b) optionally substituted heteroaryl, (c) arylalkyl, (d) heteroarylalkyl, or (e) a group of the formula -CH(R3)(R4); R is a residue selected from: alkyl, alkenyl or alkynyl each of which is optionally substituted with a group selected from: amino, NR1R2, CONR1R2, NR2COR1, OH, SOR1, SO2R1, SH, CN, NO2, an alicyclic compound, Z-R1 or cycloalkyl; and X is a physiologically acceptable anion. Representative compounds include (R)-3-[(3-fluoro-phenyl)-m-tolyl-methoxycarbonyloxy]-1-(2-oxo-2-thiophen-2-yl-ethyl)-1-azonia-bicyclo[2.2.2]octane chloride, (R)-3-[bis-(3-fluoro-phenyl)-methoxycarbonyloxy]-1-(2-oxo-2-pyridin-4-yl-ethyl)-1-azonia-bicyclo[2.2.2]octane bromide, (R)-3-[bis-(3-fluoro-phenyl)-methoxycarbonyloxy]-1-(2-phenoxy-ethyl)-1-azonia-bicyclo[2.2.2]octane bromide, (R)-3-(3-bromo-benzyloxycarbonyloxy)-1-(2-oxo-2-thiophen-2-yl-ethyl)-1-azonia-bicyclo[2.2.2]octane chloride, and (R)-3-(9H-fluoren-9-yloxycarbonyloxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane iodide. Further disclosed is a pharmaceutical composition which comprises a compound as defined above in admixture with one or more pharmaceutically acceptable carriers and/or excipients, for the prevention and/or treatment of any broncho-obstructive or inflammatory disease such as asthma, chronic bronchitis or chronic obstructive pulmonary disease (COPD).
Patent NZ-591221-A (NZ)
Title: Using engine and cartridge thermistors to determine how long to open a fuel valve to charge the cylinder
Inventor: CORDEIRO PIERRE
IPC: F02M21/02
Filed: 2011-02-17
Abstract: Disclosed is a fastening apparatus with fastening elements driven by a piston mounted within a cylinder of an internal combustion engine and forming, with a cylinder head, a combustion chamber. The apparatus includes a cartridge housing for a gas cartridge, means for injecting gas from a cartridge into the combustion chamber and a management module, with a thermistor being provided to be subjected to the temperature of the chamber. A second thermistor cartridge is provided to be subjected to the temperature of the gas cartridge disposed in the cartridge housing. Both thermistors are mounted for transmitting their temperature information to the management module. The management module is operable for managing the temperature information and determining the opening time of the injection means. The cartridge housing extends substantially in parallel to the piston in the casing of the apparatus, the engine thermistor is implanted into the combustion chamber and the cartridge thermistor is implanted into the cartridge housing.